Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Finance Watch: 2021 Is Now Two Away From 100 Biopharma IPOs

Three Health Care-Focused SPACs Also Went Public

Executive Summary

Public Company Edition: Entrada’s initial public offering grossed $181.5m while Aura raised $75.6m and Biofrontera brought in $18m. Also, AnaptysBio received $250m in Jemperli royalty deal and 4D Molecular Therapeutics grossed $118.8m in a follow-on offering.

You may also be interested in...



Pipeline Watch: Phase III Readouts In Breast And Liver Cancer Plus COVID-19

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Positive Signs For Valneva’s COVID-19 Vaccine, But Efficacy Data And Orders Still Lacking

Immunogenicity data from Valneva’s COV-COMPARE study are encouraging, but the inactivated vaccine will need proper efficacy data to gain a toehold in a crowded market.

IPO Update: Average Return Turns Negative For Newly Public Biopharma Firms

With 88 initial public offerings in the US through the end of the third quarter of 2021, the biopharma industry is two IPOs ahead of the full-year 2020 total, but with an average return of -4% momentum may slow.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC145324

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel